Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Dynaxaparin - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/Dynaxaparin

Approved

STANDARD

Dynaxaparin

Brawn Laboratories Ltd.🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: 2437c12e2fa5a15a
Company: Brawn Laboratories Ltd.
Type: Standard

Approval Details

Approval Id: 2437c12e2fa5a15a
Drug Approval Philippines Name: Dynaxaparin
Product Name: Dynaxaparin
Registration Number: BRP-041-14
Brand Name: Dynaxaparin
Generic Name: Enoxaparin sodium
Dosage Form: Solution for Injection (SC)
Dosage Strength: 4000 IU anti-Factor Xa (equivalent to 40 mg)/0.4 mL
Manufacturer: Brawn Laboratories Ltd.
Importer: Ambica International Corporation
Distributor: Dynasty Pharmaceuticals
Issuance Date: 24 January 2025
Expiry Date: 09 December 2025
Pharmacologic Category: Antithrombotic Agents
Classification: Prescription Drug (RX)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

2437c12e2fa5a15a

Type

Standard

Back to Philippines FDA Approvals